TEAD emerges as a promising therapeutic target for metabolic diseases such as MASLD
April 8, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, shows different occurrence between sexes, being less prevalent in premenopausal women than in men or postmenopausal women.